Breakthrough Cancer Pain Monographs
Breakthrough cancer pain (BTCP) is a common occurrence in cancer patients that can be treated by a number of immediate-release (IR) opioids, some of which are specifically labeled for this use (i.e., IR fentanyl). However, the predominant use of breakthrough pain products, particularly the IR fentanyls, is off-label for noncancer pain-related diagnoses. Based on the National Survey on Drug Use and Health, medications are commonly being misused and abused by patients and acquaintances of patients. Education is needed around the safe use of opioid analgesics and, more specifically, the IR fentanyl medications for BTCP. This educational program is specifically designed to support this objective.